Brought to you by 
Flagship Ventures launches Evelo and provides $35mm in Series A funding
12 Jul 2017
Executive Summary
Flagship Ventures launched Evelo Therapeutics, a company focused on microbiome therapies for cancer, and contributed $35mm as the sole investor in the start-up's Series A round.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Flagship Ventures launches Evelo and provides $35mm in Series A funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice